Roxadustat attenuates brain injury in mice with heat stroke by regulating mitochondrial fission and fusion

Objective To explore the protective effect and underlying mechanism of roxadustat (FG-4592), hypoxia-inducible factor-α (HIF-α) prolyl hydroxylase inhibitor, on brain injury caused by heat stroke (HS). Methods A total of 140 male C57BL/6J mice (6~8 weeks old, weighing 18~22 g) were subjected, and 4...

Full description

Bibliographic Details
Published in:	陆军军医大学学报
Main Authors:	10.16016/j.2097-0927.202405009, HUANG Xueyan, SHEN Tingting
Format:	Article
Language:	Chinese
Published:	Editorial Office of Journal of Army Medical University 2024-10-01
Subjects:	roxadustat heat stroke oxidative stress mitochondria hypoxia-inducible factor-1α
Online Access:	https://aammt.tmmu.edu.cn/html/202405009.htm

Similar Items

Roxadustat: Not just for anemia
by: Xiaoyu Zhu, et al.
Published: (2022-08-01)

Roxadustat for Patients with Posttransplant Anemia: A Narrative Review
by: Xiaoxiao Tang, et al.
Published: (2023-11-01)

A Pharmacodynamic Evaluation of the Protective Effects of Roxadustat Against Hypoxic Injury at High Altitude
by: Guo Q, et al.
Published: (2023-01-01)

Effects of Roxadustat on Erythropoietin Production in the Rat Body
by: Yukiko Yasuoka, et al.
Published: (2022-02-01)

Issues on clinical application of hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat
by: TU Yan, et al.
Published: (2020-01-01)

A Case Report of Hypothyrotropin Hypothyroidism Caused by Roxadustat
by: YAN Xuelian, et al.
Published: (2025-03-01)

Roxadustat attenuates heat stress-induced apoptosis and senescence in renal tubular epithelial cells by upregulating HIF-1α
by: SONG Yongwei, et al.
Published: (2024-05-01)

Research advances of roxadustat in the treatment of various diseases
by: Tian Qian-qian, et al.
Published: (2022-07-01)

Influencing factors of clinical efficacy of roxadustat among hemodialysis patients
by: Wenhui Wu, et al.
Published: (2024-12-01)

The role of roxadustat in chronic kidney disease patients complicated with anemia
by: Jie Liu, et al.
Published: (2023-03-01)

Research progress on roxadustat treatment for renal anemia
by: HU Bao-li, HU Bin
Published: (2022-09-01)

Roxadustat improves diabetic myocardial injury by upregulating HIF-1α/UCP2 against oxidative stress
by: Tingting Fang, et al.
Published: (2025-02-01)

Roxadustat Attenuates the Disruption of Epithelial Tight Junction in Caco2 Cells and a Rat Model of CKD Through MicroRNA-223
by: Ning Qu, et al.
Published: (2022-04-01)

Roxadustat for the Treatment of Early Post-Transplantation Anemia
by: Louis Guenal, et al.
Published: (2025-10-01)

Randomized Study on the Efficacy of Standard Versus Low Roxadustat Dose for Anemia in Patients on Peritoneal Dialysis
by: Zhikai Yang, et al.
Published: (2022-03-01)

Rasd1 aggravates white matter injury after subarachnoid hemorrhage in rats by promoting ferroptosis in oligodendrocytes
by: 10.16016/j.2097-0927.202302069, et al.
Published: (2023-09-01)

Antianemia Drug Roxadustat (FG-4592) Protects Against Doxorubicin-Induced Cardiotoxicity by Targeting Antiapoptotic and Antioxidative Pathways
by: Guangfeng Long, et al.
Published: (2020-08-01)

Case report: Roxadustat overdose in an anemia patient of chronic kidney disease: insight beyond insignificant consequence
by: Long-Guang Zhang, et al.
Published: (2024-08-01)

Roxadustat reduced the risk of perioperative complication arising from the treatment of cardiac paraganglioma: A case report
by: Dong Wang, et al.
Published: (2023-09-01)

Roxadustat on Renal Anemia with Macroinflammation: A Retrospective Cohort Study
by: Yan Tu, et al.
Published: (2024-03-01)

The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease
by: Ryujiro Hara, et al.
Published: (2021-11-01)

The HIFα-Stabilizing Drug Roxadustat Increases the Number of Renal Epo-Producing Sca-1<sup>+</sup> Cells
by: Aline Jatho, et al.
Published: (2022-02-01)

Roxadustat: Do we know all the answers?
by: Qiu-Yu Li, et al.
Published: (2023-05-01)

Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study
by: Emiko Otsuka, et al.
Published: (2024-12-01)

Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat
by: Serina Kita, et al.
Published: (2024-09-01)

Roxadustat for the treatment of anemia in patients with chronic kidney disease: a Meta-analysis
by: WANG Rui, et al.
Published: (2019-01-01)

A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness
by: Jie Liu, et al.
Published: (2024-05-01)

Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study
by: Xiaomeng Zheng, et al.
Published: (2023-12-01)

Roxadustat as a Hypoxia-Mimetic Agent: Erythropoietic Mechanisms, Bioanalytical Detection, and Regulatory Considerations in Sports Medicine
by: Elena-Christen Creangă, et al.
Published: (2025-09-01)

Safety of Roxadustat in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis
by: Patricia Martínez-Miguel, et al.
Published: (2025-10-01)

The Roxadustat (FG-4592) ameliorates tubulointerstitial fibrosis by promoting intact FGF23 cleavage
by: Jing Wang, et al.
Published: (2025-04-01)

Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia
by: Tian Xu, et al.
Published: (2025-12-01)

Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis
by: Yangyang Zhang, et al.
Published: (2023-10-01)

Roxadustat alleviates cisplatin-induced acute kidney injury by regulating fatty acid oxidation and mitochondrial function
by: Xialin Li, et al.
Published: (2025-12-01)

Budget impact analysis on the Italian healthcare system of roxadustat for the treatment of anemia due to chronic kidney disease
by: Chiara Bini, et al.
Published: (2024-09-01)

Roxadustat promotes osteoblast differentiation and prevents estrogen deficiency-induced bone loss by stabilizing HIF-1α and activating the Wnt/β-catenin signaling pathway
by: Luyao Li, et al.
Published: (2022-05-01)

A critical review of Roxadustat formulations, solid state studies, and analytical methodology
by: Rupali Mahajan, et al.
Published: (2023-06-01)

Roxadustat in CKD and transplant patients: A new era in anemia management
by: Muhammad Tassaduq Khan, et al.
Published: (2025-03-01)

Roxadustat promotes allograft recovery after kidney transplantation: A prospective, multicenter, randomized controlled trial
by: Mao-Lin Ma, et al.
Published: (2025-08-01)

Randomized Trial of Lower-Dose Roxadustat Efficacy and Safety in Non–Dialysis-Dependent CKD-Associated Anemia
by: Ping Li, et al.
Published: (2025-04-01)